Pentostatin: Impact on outcome in hairy cell leukemia
Pentostatin: Impact on outcome in hairy cell leukemia
复制标题
DOI：
10.1016/j.hoc.2006.06.001
复制
发表时间：
2006-10-01
影响因子：
2.4
通讯作者：
Grever, Michael R.
中科院分区：
文献类型：
--
作者：
Grever, Michael R.
在使用嘌呤核苷类似物后，在治疗毛细胞白血病患者方面取得了重大进展。他汀类药物和克拉曲滨同样有效，并具有令人印象深刻的长期有效性。外周血细胞计数的逐渐但持续的改善使大多数患者能够在门诊使用五肽抑素进行管理。克拉曲滨提供了方便的单一疗程的给药。与这两种药物的直接比较研究不太可能在改善方面产生显著差异。患者仍在复发，总体生存曲线并未达到平台期，这表明治愈尚未得到保障。未来的研究应该针对最小残留疾病的优化治疗，以及对支持性护理的更明确的定义。
Major advances in the management of patients who have hairy cell leukemia have been made following the use of purine nucleoside analogs. Pentostatin and cladribine are equally effective, and have impressive long-term effectiveness. The gradual, but relentless, improvement in the peripheral blood counts enables the outpatient management with pentostatin in most patients. Cladribine affords the convenience of a single course of administration. A direct comparative study with these two agents is unlikely to yield dramatic differences in improvement. Patients still relapse, and the overall survival curves have not reached a plateau, which indicates that cure has not been secured. Future studies should be directed to optimizing the therapy for minimal residual disease as well as clearer definition of supportive care.